0000000000311662

AUTHOR

Koon K. Teo

showing 8 related works from this author

Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk

2019

Abstract Aims Studies have shown a non-linear relationship between systolic blood pressure (SBP) and diastolic blood pressure (DBP) and outcomes, with increased risk observed at both low and high blood pressure (BP) levels. We hypothesized that the BP-risk association is different in individuals with and without diabetes at high cardiovascular risk. Methods and results We identified patients with (N = 11 487) or without diabetes (N = 19 450), from 30 937 patients, from 133 centres in 44 countries with a median follow-up of 56 months in the ONTARGET/TRANSCEND studies. Patients had a prior history of stroke, myocardial infarction (MI), peripheral artery disease, or were high-risk diabetics. P…

Ramiprilmedicine.medical_specialtyhypertensionSystoleAngiotensin-Converting Enzyme Inhibitors030204 cardiovascular system & hematologyPeripheral Arterial Disease03 medical and health sciences0302 clinical medicineRamiprilDiastoleRisk FactorsInternal medicineDiabetes mellitusDiabetes MellitusmedicineHumanshigh cardiovascular riskTelmisartan030212 general & internal medicineMyocardial infarctionStrokeRetrospective StudiesHeart Failurediabetesbusiness.industryHazard ratioblood pressureBlood Pressure Determinationmedicine.diseasestrokeHospitalizationmyocardial infarctionBlood pressureCardiovascular DiseasesCase-Control StudiesHeart failureCardiologyDrug Therapy CombinationTelmisartanCardiology and Cardiovascular MedicinebusinessAngiotensin II Type 1 Receptor Blockersmedicine.drugEuropean Heart Journal
researchProduct

Ambulatory Blood Pressure Values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET)

2012

In the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial, telmisartan (T; 80 mg daily) and ramipril (R; 10 mg daily) caused similar clinic blood pressure (BP) reductions, with a similar incidence of cardiovascular and renal events. The R+T combination lowered clinic BP somewhat more with no further cardiovascular or renal protection. The aim of this substudy was to see whether these clinic BP changes reflected the changes of 24-hour BP, a BP with a better prognostic value. In 422 patients in whom 24-hour BP monitoring was performed either before or after 6 to 24 months of treatment, demographic and clinical characteristics were similar in the 3 treated groups.…

RamiprilMalemedicine.medical_specialtyAmbulatory blood pressureDiastoleAngiotensin-Converting Enzyme InhibitorsBlood PressureBenzoateslaw.inventionRandomized controlled trialRamiprillawInternal medicineInternal MedicinemedicineHumansLongitudinal StudiesTelmisartanAntihypertensive AgentsAgedbusiness.industryambulatory blood pressure antihypertensive treatment high cardiovascular risk angiotensin-converting enzyme inhibitors angiotensin receptor blockersMED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREBlood Pressure Monitoring AmbulatoryMiddle AgedEndocrinologyBlood pressureTreatment OutcomeTarget drugAmbulatoryHypertensionCardiologyBenzimidazolesDrug Therapy CombinationFemaleTelmisartanbusinessmedicine.drug
researchProduct

Visit-to-visit blood pressure variability and renal outcomes: results from ONTARGET and TRANSCEND trials.

2020

AIMS There is conflicting evidence on whether in treated hypertensive patients the risk of renal outcomes is associated with visit-to-visit SBP variability. Furthermore, limited evidence is available on how important is SBP variability for prediction of renal outcomes compared with on-treatment mean SBP. We addressed these issues in 28 790 participants of the Ongoing Treatment Alone and in combination with Ramipril Global End point Trial and Telmisartan Randomized Assessment Study in ace iNtolerant Subjects with Cardiovascular Disease trials. METHODS AND RESULTS SBP variability was expressed as the coefficient of variation of the mean with which it showed no relationship. SBP variability an…

Ramiprilmedicine.medical_specialtyPhysiologyBlood Pressure030204 cardiovascular system & hematologyurologic and male genital diseases03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineInternal MedicineMedicineHumanscardiovascular diseases030212 general & internal medicineAntihypertensive AgentsCreatininebusiness.industryIncidence (epidemiology)Confoundingmedicine.diseaseBlood pressureMean blood pressurechemistryCreatinineHypertensionCardiologyKidney Failure ChronicMicroalbuminuriaTelmisartanCardiology and Cardiovascular Medicinebusinesscirculatory and respiratory physiologymedicine.drugJournal of hypertension
researchProduct

Resting heart rate and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk analysis from the ONTARGET/TRANSC…

2018

Abstract Aims Resting heart rate (RHR) has been shown to be associated with cardiovascular outcomes in various conditions. It is unknown whether different levels of RHR and different associations with cardiovascular outcomes occur in patients with or without diabetes, because the impact of autonomic neuropathy on vascular vulnerability might be stronger in diabetes. Methods and results We examined 30 937 patients aged 55 years or older with a history of or at high risk for cardiovascular disease and after myocardial infarction, stroke, or with proven peripheral vascular disease from the ONTARGET and TRANSCEND trials investigating ramipril, telmisartan, and their combination followed for a m…

Malemedicine.medical_specialtyRestHeart failure030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineHeart RateRisk FactorsInternal medicineDiabetes mellitusmedicineDiabetes MellitusHumansMyocardial infarctionProspective StudiesONTARGETStrokeProportional hazards modelbusiness.industryHazard ratioDiabetesAtrial fibrillation030229 sport sciencesMiddle Agedmedicine.diseaseCardiovascular riskMyocardial infarctionBlood pressureCardiovascular DiseasesHeart Disease Risk FactorsHeart failureCardiologyBlood pressureFemaleCardiology and Cardiovascular MedicinebusinessTRANSCENDEuropean heart journal
researchProduct

Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials

2017

Summary Background Studies have challenged the appropriateness of accepted blood pressure targets. We hypothesised that different levels of low blood pressure are associated with benefit for some, but harm for other outcomes. Methods In this analysis, we assessed the previously reported outcome data from high-risk patients aged 55 years or older with a history of cardiovascular disease, 70% of whom had hypertension, from the ONTARGET and TRANSCEND trials investigating ramipril, telmisartan, and their combination, with a median follow-up of 56 months. Detailed descriptions of randomisation and intervention have already been reported. We analysed the associations between mean blood pressure a…

Ramiprilmedicine.medical_specialtybusiness.industryMedicine (all)General Medicine030204 cardiovascular system & hematologymedicine.diseasePrehypertensionSurgery03 medical and health sciences0302 clinical medicineBlood pressureMean blood pressureHeart failureInternal medicinemedicineCardiology030212 general & internal medicineMyocardial infarctionTelmisartanbusinessStrokemedicine.drug
researchProduct

Systolic Blood Pressure Variation and Mean Heart Rate Is Associated With Cognitive Dysfunction in Patients With High Cardiovascular Risk

2015

Abstract— Elevated systolic blood pressure (SBP) correlates to cognitive decline and incident dementia. The effects of heart rate (HR), visit to visit HR variation, and visit to visit SBP variation are less well established. Patients without preexisting cognitive dysfunction (N=24 593) were evaluated according to mean SBP, SBP visit to visit variation (coefficient of variation [standard deviation/mean×100%], CV), mean HR, and visit to visit HR variation (HR-CV) in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease. Cognitive function was assessed with min…

MalePredictive Value of TestAngiotensin-Converting Enzyme InhibitorsBlood PressureBenzimidazoleBenzoatesRamiprilRetrospective StudieHeart RateRisk FactorsCardiovascular DiseaseTelmisartanCognitive declineMultivariate AnalysiRandomized Controlled Trials as TopicAged 80 and overmedicine.diagnostic_testIncidenceMiddle AgedstrokeAntihypertensive Agentmyocardial infarctionCardiovascular DiseasesHypertensionCardiologyDrug Therapy CombinationFemaleHumanmedicine.drugRamiprilmedicine.medical_specialtyBenzoateFollow-Up StudieCognition DisorderPredictive Value of TestsInternal medicineHeart rateInternal MedicinemedicineHumansDementiaAntihypertensive AgentsAgedRetrospective StudiesMini–Mental State Examinationbusiness.industryRisk FactorAngiotensin-Converting Enzyme InhibitorOdds ratiomedicine.diseaseConfidence intervalBlood pressureMultivariate AnalysisPhysical therapyBenzimidazolesCognition DisordersbusinessFollow-Up StudiesHypertension
researchProduct

Renal outcomes and blood pressure patterns in diabetic and nondiabetic individuals at high cardiovascular risk

2021

Background Diabetes and hypertension are risk factors for renal and cardiovascular outcomes. Data on the association of achieved blood pressure (BP) with renal outcomes in patients with and without diabetes are sparse. We investigated the association of achieved SBP, DBP with renal outcomes and urinary albumin excretion (UAE) in people with vascular disease. Methods In this pooled analysis, we assessed renal outcome data from high-risk patients aged 55 years or older with a history of cardiovascular disease, 70% of whom had hypertension, randomized to The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial and to Telmisartan Randomized Assessment Study in ACE In…

Ramiprilmedicine.medical_specialtyPhysiologyRenal functionAngiotensin-Converting Enzyme InhibitorsBlood Pressure030204 cardiovascular system & hematologyBenzoates03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRisk FactorsInternal medicineDiabetes mellitusDiabetes MellitusInternal MedicinemedicineHumans030212 general & internal medicineCreatininebusiness.industryHazard ratioMiddle Agedmedicine.diseasechemistryCardiovascular DiseasesHeart Disease Risk FactorsHypertensionAlbuminuriaMicroalbuminuriamedicine.symptomTelmisartanCardiology and Cardiovascular Medicinebusinessmedicine.drugJournal of Hypertension
researchProduct

Cardiovascular outcomes in patients at high cardiovascular risk with previous myocardial infarction or stroke.

2021

BACKGROUND Guidelines recommend to start blood pressure (BP)-lowering drugs also according to cardiovascular risk including history of cardiovascular events. We hypothesized that in patients with a history of myocardial infarction (MI), stroke, both or none of those, the index events predict the next event and have different SBP risk associations to different cardiovascular outcomes. DESIGN AND MEASUREMENTS In this pooled posthoc, nonprespecified analysis, we assessed outcome data from high-risk patients aged 55 years or older with a history of cardiovascular events or proven cardiovascular disease, randomized to the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint…

Ramiprilmedicine.medical_specialtyPhysiologyMyocardial InfarctionAngiotensin-Converting Enzyme InhibitorsRisk FactorsInternal medicineInternal MedicinemedicineHumansMyocardial infarctionStrokebusiness.industryProportional hazards modelHazard ratiomedicine.diseaseConfidence intervalClinical trialStrokeTreatment OutcomeCardiovascular DiseasesHeart Disease Risk FactorsCardiologyTelmisartanCardiology and Cardiovascular Medicinebusinessmedicine.drugJournal of hypertension
researchProduct